Frontline Therapy of CLL: Evolving Treatment Paradigm

Current Hematologic Malignancy Reports
Craig S Boddy, Shuo Ma

Abstract

Chronic lymphocytic leukemia (CLL) has multiple current frontline therapy options, including chemoimmunotherapy (CIT) and most recently, ibrutinib. Here, we review the most recent updates in the frontline treatment of CLL, including updates in CIT, updates in targeted therapies, and ongoing clinical trials. Ibrutinib was FDA-approved for the upfront treatment of CLL in 2016 after being studied in older patients and those with 17p deletions or TP53 mutations. The introduction of ibrutinib has dramatically changed the treatment paradigm of CLL. Recent updates in CIT include that immunoglobulin heavy chain variable (IGHV) gene mutation status is strongly predictive of response to CIT. Regarding targeted therapy, next-generation BTK and PI3K inhibitors are currently being studied in the upfront treatment of CLL, which may have less toxicity than their first-generation counterparts. Other novel targeted therapies are being studied in the frontline setting, most notably venetoclax including in combinations, with hopes to achieve chemotherapy-free, time-limited treatment options. Multiple key ongoing phase 3 clinical trials will be answering these important clinical questions.

References

May 31, 2001·British Journal of Haematology·G PapakonstantinouR Hehlmann
Mar 18, 2009·Immunological Reviews·Tomohiro Kurosaki, Masaki Hikida
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba
Mar 17, 2012·Blood·Paolo Ghia, Federico Caligaris-Cappio
Jun 21, 2012·Blood·Jennifer A WoyachJohn C Byrd
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenChristopher F E Pocock
Dec 8, 2015·The New England Journal of Medicine·Jan A BurgerUNKNOWN RESONATE-2 Investigators
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Dec 8, 2015·The New England Journal of Medicine·John C ByrdRichard R Furman
Dec 1, 2010·Surgical Pathology Clinics·Robert Paul Hasserjian
Mar 1, 2017·Current Treatment Options in Oncology·Benjamin N Voorhies, Deborah M Stephens
Mar 23, 2017·Blood·Kirsten FischerMichael Hallek
Aug 5, 2017·Leukemia & Lymphoma·Lucile SeséUNKNOWN Foch Hospital Lung Immune Deficiencies study group
Sep 26, 2017·Expert Opinion on Investigational Drugs·Pawel Robak, Tadeusz Robak

❮ Previous
Next ❯

Citations

Jun 17, 2020·International Journal of Laboratory Hematology·Camille DebordMarie C Béné
Dec 5, 2018·Case Reports in Hematology·Heather KatzMohamed Alsharedi
Jul 17, 2020·Expert Review of Hematology·Tsering Gyalpo LamaSusan O'Brien
Jul 13, 2018·Frontiers in Oncology·Emanuela RosatiPaolo Sportoletti
Mar 7, 2020·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Daniel R RichardsonJohn F P Bridges

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Bernard L MariniAnthony J Perissinotti
Current Hematologic Malignancy Reports
Xavier C BadouxWilliam G Wierda
Current Treatment Options in Oncology
Krzysztof JamroziakJan Walewski
© 2022 Meta ULC. All rights reserved